BEGIN:VCALENDAR
PRODID:-//AddEvent Inc//AddEvent.com v1.7//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:STANDARD
DTSTART:20261101T010000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20260308T030000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Room: Skagit 3\, Lower Level\, Arch at 800 Pike\n\nPresented by: Sean Glenn\, PhD Roswell Park Cancer Institute\n\nThe rise of NGS-based MRD technologies provides a major advantage over current hemato-oncology methods by enabling both enhanced sensitivity in detection and more comprehensive genomic insights. Hear from Dr. Sean Glenn\, Roswell Park Cancer Institute\, as he shares his insights using the SureSeq™ Myeloid MRD Plus NGS Panel* in an expanded second phase retrospective cohort study of research specimens collected from patients undergoing AML treatment. \n\n*Research Use Only\; Not for Use in Diagnostic Procedures \n\n\n\n------\n\nCreate your own Add to Calendar links with addevent.com/r/a \n
X-ALT-DESC;FMTTYPE=text/html:Room: <strong>Skagit 3, Lower Level, Arch at 800 Pike</strong><br><br>Presented by: <strong>Sean Glenn</strong>, PhD Roswell Park Cancer Institute<br><br>The rise of NGS-based MRD technologies provides a major advantage over current hemato-oncology methods by enabling both enhanced sensitivity in detection and more comprehensive genomic insights. Hear from Dr. Sean Glenn, Roswell Park Cancer Institute, as he shares his insights using the SureSeq™ Myeloid MRD Plus NGS Panel* in an expanded second phase retrospective cohort study of research specimens collected from patients undergoing AML treatment. <br /><strong><br /></strong><em>*Research Use Only; Not for Use in Diagnostic Procedures <br /></em><strong><br /></strong><br /><br />------<br /><br />Create your own Add to Calendar links with addevent.com/r/a <br>
UID:ba187707c32f4449b77e466a6f83e5d8addeventcom
SUMMARY:AMP Workshop — Lessons learned: Evaluating ultra-high sensitive NGS in the future of AML MRD testing
DTSTART;TZID=America/Los_Angeles:20261111T120000
DTEND;TZID=America/Los_Angeles:20261111T125000
DTSTAMP:20260825T035335Z
TRANSP:OPAQUE
STATUS:CONFIRMED
SEQUENCE:0
LOCATION:Seattle\, Washington\, USA
X-MICROSOFT-CDO-BUSYSTATUS:BUSY
BEGIN:VALARM
TRIGGER:-PT30M
ACTION:DISPLAY
DESCRIPTION:Reminder
END:VALARM
END:VEVENT
END:VCALENDAR